These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22230789)

  • 1. Treatment of Paget's disease of bone.
    Lojo Oliveira L; Torrijos Eslava A
    Reumatol Clin; 2012; 8(4):220-4. PubMed ID: 22230789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Paget's disease of the bones: diagnosis and treatment].
    Jacobs JW; Huisman AM; van Paassen HC; Bijlsma JW
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):719-25. PubMed ID: 10347626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and management of Paget's disease of bone].
    Hashimoto J; Yoshikawa H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():56-64. PubMed ID: 18161082
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated Hypercalcemia in a patient with Paget's disease.
    Hung HC; Ou HY; Huang JS; Chuang MC; Wu TJ
    Kaohsiung J Med Sci; 2008 Mar; 24(3):152-6. PubMed ID: 18364276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurological complications of Paget's disease of bone].
    Foidart M; Reginster JY; Franchimont P
    Rev Med Liege; 1989 Jun; 44(11):396-401. PubMed ID: 2664967
    [No Abstract]   [Full Text] [Related]  

  • 9. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES; Lyles KW; Singer FR; Meunier PJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical aspects and therapy of Paget's disease (osteitis deformans)].
    Ringe JD
    Dtsch Med Wochenschr; 1983 Aug; 108(31-32):1207-12. PubMed ID: 6223799
    [No Abstract]   [Full Text] [Related]  

  • 11. The diagnosis of Paget's disease.
    Pande I
    Practitioner; 2001 Sep; 245(1626):730-5. PubMed ID: 11584586
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of osteodystrophia deformans (Paget's disease)].
    Jesserer H
    Clin Ter; 1974 Jun; 69(6):501-15. PubMed ID: 4367627
    [No Abstract]   [Full Text] [Related]  

  • 13. Monostotic Paget's disease of the tibia in Korea.
    Lee CH; Han SH; Yoon BY; Lee YW
    Clin Rheumatol; 2004 Aug; 23(4):381-2. PubMed ID: 15293109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paget's disease with osteolytic lesions: combining medical and surgical treatments.
    Brumsen C; Bloem RM; Papapoulos SE
    Neth J Med; 1992 Jun; 40(5-6):292-8. PubMed ID: 1436268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Paget's disease of bone.
    Melick RA
    Med J Aust; 1985 Oct; 143(9):394-7. PubMed ID: 2932626
    [No Abstract]   [Full Text] [Related]  

  • 18. [Paget's disease and hypercalcemia: coincidence or causal relationship?].
    Green I; Altman A
    Harefuah; 2009 Oct; 148(10):708-10, 733. PubMed ID: 20073401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical assessment of Paget's disease of bone.
    Shankar S; Hosking DJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.